Pericarditis Drugs

Global Pericarditis Drugs Market to Reach US$4.7 Billion by 2030

The global market for Pericarditis Drugs estimated at US$3.8 Billion in the year 2024, is expected to reach US$4.7 Billion by 2030, growing at a CAGR of 3.4% over the analysis period 2024-2030. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), one of the segments analyzed in the report, is expected to record a 3.6% CAGR and reach US$2.5 Billion by the end of the analysis period. Growth in the Colchicine Drugs segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.0 Billion While China is Forecast to Grow at 6.6% CAGR

The Pericarditis Drugs market in the U.S. is estimated at US$1.0 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$969.0 Million by the year 2030 trailing a CAGR of 6.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Pericarditis Drugs - Key Trends and Drivers

The pericarditis drugs market has seen notable developments, driven by the increase in cardiovascular diseases. Cardiovascular conditions remain the leading cause of global mortality, with conditions like coronary heart disease and cerebrovascular disease claiming about 17.9 million lives annually. Pericarditis often follows cardiac surgeries and heart attacks, linking the high incidence of cardiovascular conditions directly to increased demand for pericarditis treatments. The recurrence of pericarditis, particularly after the first episode, which affects nearly 30% of patients, further amplifies this demand. As such, ongoing research and development in new therapies for pericarditis are crucial, as seen in several clinical trials focusing on drugs like KPL-914 and Dexamethasone, which are exploring more effective and safer treatment avenues.

In response to the burgeoning need, the pericarditis drugs market is witnessing significant trends in drug development and therapy improvements. The NSAIDs segment, for example, is expected to dominate the market due to its effectiveness in reducing symptoms such as chest pain, a primary complaint of pericarditis patients. Advancements in pharmacotherapy are also being noted, with newer drugs targeting the NLRP3 inflammasome/IL-1 axis showing promise for recurrent cases. The geographical dominance of North America in this market is attributed to high cardiac disease prevalence, substantial healthcare R&D, and heightened patient awareness regarding heart-related inflammations. However, challenges such as the side effects of drugs and the high costs associated with advanced therapies could restrain market growth. Nonetheless, the ongoing clinical trials and increasing investments in health infrastructure globally are expected to drive forward the market, ensuring extensive growth and development in the treatment of pericarditis.

 

 

SCOPE OF STUDY:

The report analyzes the Pericarditis Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Drug Class (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Colchicine Drugs, Other Drug Classes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 52 Featured) -

• AbbVie Inc.
• Amneal Pharmaceuticals LLC
• Aurobindo Pharma Ltd.
• Bayer AG
• Bristol-Myers Squibb Company
• Cardiol Therapeutics Inc.
• Dr. Reddy`s Laboratories Ltd
• Hikma Pharmaceuticals plc
• Johnson & Johnson Services, Inc.
• Kiniksa Pharmaceuticals Corp.
• Lupin Pharmaceutical, Inc.
• Novartis International AG
• Takeda Pharmaceutical Co. Ltd
• Teva Pharmaceutical Industries Ltd (Israel)
• Viatris Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.